Highlights Abliva AB

Equities

ABLI

SE0002575340

Market Closed - Nasdaq Stockholm Other stock markets 08:51:45 13/05/2024 pm IST			5-day change	1st Jan Change
0.1918 ^SEK	+0.95%		+6.91%	-21.87%

23/02	Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
2023	Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23/02	CI
Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	20/12	CI
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11	CI
Abliva AB and Owl Therapeutics Enter into Licensing and Collaboration Agreement for NeuroSTAT in Traumatic Brain Injury	15/11	CI
Abliva AB Achieves Important Milestone in the Ongoing FALCON Study	11/23/11	CI
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/23/18	CI
Abliva AB Announces First Patient Dosed in the Falcon Study	28/23/28	CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23	CI
Abliva AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	24/23/24	CI
Abliva AB Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333	06/22/06	CI
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/22/22	CI
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	19/22/19	CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2022	01/22/01	CI
Abliva AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22/22/22	CI
Abliva AB Reports Earnings Results for the Full Year Ended December 31, 2021	22/22/22	CI
US Food and Drug Administration Approves Abliva's Investigational New Drug Application for KL1333	25/21/25	CI
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	19/21/19	CI
Abliva's NV354 targets fatal paediatric disease	27/21/27	CI
Abliva AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	19/21/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Abliva AB

Equities

ABLI

SE0002575340

Highlights

Filters